UOC
ROIV icon

UBS O'Connor’s Roivant Sciences ROIV Stock Holding History

UBS O'Connor’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,819
Closed -$432K – 446
2025
Q1 		$432K Sell
42,819
-136,447
-76% -$1.48M 0.01% 225
2024
Q4 		$2.12M Buy
179,266
+32,329
+22% +$382K 0.05% 148
2024
Q3 		$1.7M Buy
146,937
+22,720
+18% +$259K 0.04% 198
2024
Q2 		$1.31M Buy
124,217
+27,000
+28% +$296K 0.04% 258
2024
Q1 		$1.02M Sell
97,217
-101,215
-51% -$1.09M 0.03% 272
2023
Q4 		$2.23M Buy
198,432
+34,221
+21% +$334K 0.07% 157
2023
Q3 		$1.92M Sell
164,211
-26,000
-14% -$294K 0.03% 251
2023
Q2 		$1.92M Buy
190,211
+28,386
+18% +$254K 0.04% 303
2023
Q1 		$1.19M Buy
161,825
+19,325
+14% +$159K 0.03% 388
2022
Q4 		$1.14M Buy
+142,500
New +$793K 0.02% 551

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

UBS O'Connor's ROIV Position: Q2 2025 in Review

UBS O'Connor sold out of Roivant Sciences (ROIV) in Q2 2025, closing a stake of 42,819 shares — an estimated $432K sold.

UBS O'Connor first reported a position in ROIV in Q4 2022 and held it in 10 quarters. The position peaked at $2.23M in Q4 2023. 338 funds tracked by Wall St. Rank hold ROIV as of Q2 2025.

  • UBS O'Connor reported no remaining Roivant Sciences position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 42,819 Roivant Sciences shares in Q2 2025, an estimated $432K.
  • UBS O'Connor first reported a position in Roivant Sciences in Q4 2022 and held it in 10 quarters.
  • UBS O'Connor's Roivant Sciences position peaked at $2.23M in Q4 2023.
  • 338 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.